SVA.V - Sernova Corp.

TSXV - TSXV Delayed Price. Currency in CAD
0.1500
-0.0200 (-11.76%)
As of 1:12PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.1700
Open0.1700
Bid0.1450 x N/A
Ask0.1500 x N/A
Day's Range0.1500 - 0.1700
52 Week Range0.1400 - 0.2800
Volume889,500
Avg. Volume324,398
Market Cap37.87M
Beta (5Y Monthly)0.40
PE Ratio (TTM)N/A
EPS (TTM)-0.0190
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
  • Is Sernova (CVE:SVA) In A Good Position To Deliver On Growth Plans?
    Simply Wall St.

    Is Sernova (CVE:SVA) In A Good Position To Deliver On Growth Plans?

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

  • CNW Group

    Sernova Announces Biotech Veteran as New Chief Financial Officer

    LONDON and ONTARIO, California, Oct. 24, 2019 /CNW/ -- Sernova Corp. (TSX-V:SVA.V - News) (OTCQB:SEOVF - News) (FSE:PSH.F - News), a clinical-stage regenerative medicine company, is pleased to announce that Mr. David Swetlow, CPA, CA, has joined Sernova as Chief Financial Officer. Mr. Swetlow is a veteran of the high tech and life sciences industries with over 20 years in various senior management, board, and advisory roles for start-up, acceleration, and high-growth stage companies, including multiple TSX and Nasdaq listed biotech companies amongst them QLT Inc. and Protox Therapeutics Inc. Adding a full-time CFO at this inflection point for the company with our recent announcement of initial positive early efficacy indicators for our Cell Pouch(TM) Phase I/II US clinical trial for type-1 diabetes and ongoing business development activities will accelerate execution of the company's financial, business and capital markets goals and strategies," said Dr. Philip Toleikis, President and CEO of Sernova.

  • Newsfile

    InvestmentPitch Media Video Discusses Sernova Corp's Further Validation of Cell Pouch and Therapeutic Cell Performance in Type-1 Diabetes - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - October 17, 2019) - Sernova Corp. (TSXV: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage regenerative medicine company, has reported findings that further validate Cell Pouch™ and therapeutic cell performance in Type-1 diabetes. The Cell Pouch™ is a novel implantable device, that is transplanted with therapeutic cells such as insulin producing islets. InvestmentPitch Media has produced a "video" which describes this news. If this link is not enabled, please ...

  • Did Changing Sentiment Drive Sernova's (CVE:SVA) Share Price Down By 32%?
    Simply Wall St.

    Did Changing Sentiment Drive Sernova's (CVE:SVA) Share Price Down By 32%?

    Sernova Corp. (CVE:SVA) shareholders will doubtless be very grateful to see the share price up 42% in the last...